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Breathing new life into old antibiotics: Overcoming antibacterial resistance by 
antibiotic-loaded nanogel carriers with cationic surface functionality 
Paul J. Weldrick,a Sammi Iveson,b Matthew J. Hardmanc and Vesselin N. Paunov a,* 
Multidrug-resistant pathogens are prevalent in chronic wounds. There is an urgent need to develop novel antimicrobials 
and formulation strategies that can overcome antibiotic resistance, and provide a safe alternative to traditional antibiotics. 
This work aimed to develop a novel nanocarrier for two cationic antibiotics, tetracycline and lincomycin hydrochloride which 
can potentially overcome antibiotic resistance. In this study, we report the use of surface functionalised polyacrylic 
copolymer nanogels as carriers for cationic antibiotics. These nanogels can encapsulate small cationic antimicrobial 
molecules and act as a drug delivery system. They were further functionalised with a biocompatible cationic polyelectrolyte, 
bPEI, to increase their affinity towards the negatively charged bacterial cell walls. These bPEI-coated nanocarrier-
encapsulated antibiotics were assessed against a range of wound isolated pathogens, which had been shown through 
antimicrobial susceptibility testing (AST) to be resistant to tetracycline and lincomycin.  Our data reveal that bPEI-coated 
nanogels with encapsulated tetracycline or lincomycin displayed increased antimicrobial performance against selected 
wound-derived bacteria, including strains highly resistant to the free antibiotic in solution. Additionally, our nanocarrier-
based antibiotics showed no detectable cytotoxic effect against human keratinocytes. We attribute the increase in 
antimicrobial activity of the cationically-functionalised antibiotic-loaded nanogel carriers to specific electrostatic adhesion 
to the microbial cell wall delivering a higher local antibiotic concentration, confirmed by scanning electron microscopy. Such 
nanotechnology based approach may enhance the effectiveness of a wide variety of existing antibiotics, offering a 
potentially new mechanism to overcome antibiotic resistance. 
Introduction 
Antibiotics are bactericidal or bacteriostatic to microorganisms, 
removing them from the body, or inhibiting them sufficiently that the 
host immune system can fight infection without being out competed 
by fast-growing microorganisms.1 Antibiotics can function by 
inhibiting the synthesis of the cell wall, synthesis of DNA, RNA, or 
proteins. They enter the cell by diffusing through the cell 
wall/membrane, or by energy dependent transport mechanisms.2,3 
However, antibiotic resistance emerged almost immediately after 
penicillin was used, and resistance species where already discovered 
before penicillin first began to be administered to patients.4 This 
emergence of resistance has been greatly amplified by the mis- and 
over-prescription of antibiotics.5 The lack of recent antibiotic 
discovery has tipped the balance of discovery/resistance towards 
bacteria, with an ever-increasing population of resistant species.6,7  
Modes of resistance which bacteria may employ include; expression 
efflux pumps which create an extracellular gradient reducing the 
concentration of the antibiotic in the cell; enzymatic inactivation of 
the antibiotic; decreased membrane permeability; or modification of 
the target to reduce antibiotic affinity.8 S. aureus has been studied 
extensively regarding antibiotic resistance, within six years of 
aminoglycoside introduction, resistance had already emerged via 
enzyme modification, with over 50 separate enzymes discovered.9 
When penicillinase-producing S. aureus was targeted with a semi-
synthetic analogous penicillin drug, methicillin, this soon became 
inhibited leading to MRSA strains.10 A similar pattern occurred with 
vancomycin resistance (VRSA) in 2002, with multi-drug resistance 
becoming an increasing obstacle.11,12 Spread of resistance is 
increased by bacterial ability to exchange genetic material.13 
Tetracycline is a broad-spectrum antibiotic, active against many 
clinically relevant pathogens.14 There are species such as P. 
aeruginosa, which have an intrinsic resistance due to the presence of 
multi-drug efflux transporters, and endogenous antimicrobial 
inactivation.15  Tetracycline inhibits protein synthesis by blocking the 
ribosomal site A, reducing the ability of charged aminoacyl-tRNA to 
enter the active site.16  Bacteria can commonly become resistant to 
tetracycline by the horizontal gene transfer of efflux pumps.17  
Lincomycin is a member of the lincosamide antibiotic group and was 
first used clinically in 1964.18 It demonstrates strong activity against 
Gram-positive species, but weaker activity against some Gram-
negative species.19 Similar to tetracycline, lincomycin prevents 
protein synthesis.20 However, lincomycin binds to the 23S portion of 
the 50S subunit of bacterial ribosomes causing the dissociation of 
peptidyl-tRNA.21 Bacteria can resist lincomycin by the use of multi-
drug efflux pumps.22  
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Figure 1.  (A) A schematic diagram of the swelling (pH 8) and deswelling (pH 5.5) method6 used to encapsulate tetracycline and lincomycin hydrochlorides into 
a polyacrylic acid nanocarrier (Carbopol Aqua SF1).  A biocompatible cationic polyelectrolyte (bPEI) was used to functionalise the nanocarrier surface which 
makes it non-toxic for mammalian cells, (B) The chemical formulas of polyacrylic acid (in the nanogel – partially cross-linked), bPEI, tetracycline hydrochloride, 
and lincomycin hydrochloride. (C) The mechanism for the delivery of antibiotics to the surface of bacteria. The positive charge pf the nanoparticle due to 
ionisation of the bPEI coating binds to the negatively charged surface groups of the bacterial cell wall.  The nanoparticle acts as a drug delivery vehicle for 
cationic antibiotics allowing a localised and continuously release, which can potentially overwhelm the microorganism resistance mechanisms.   
 
Previous attempts have been made to utilise antibiotics in a way 
which reduces the development of resistant strains.35 Sequential 
regimens alternating between two or more antibiotics doses at sub-
lethal concentrations has been shown to reduce collateral sensitivity 
and help preserve antimicrobial susceptibility to secondary antibiotic 
treatments, helping to limit the emergence of resistant species.23,36,37 
Synergistic antibiotic paired treatments are often more effective 
than single treatments. Novel synergistic combinations are rare, but 
have been found using high-throughput genetic dataset analysis of 
bacteria exposed to different antibiotics.24 Efforts have also been 
made in inhibiting the mRNA encoding for efflux pumps expressed in 
resistant bacteria. Anti-sense oligonucleotides have been shown to 
inhibit mRNA translation resulting in the reduced expression of efflux 
pumps, enabling once resisted antibiotics to be effective again.25 
Recently, Geilich et al. 38 reported a polymerosome based carrier of 
silver nanoparticles which show promising results against antibiotic 
resistant bacteria. Despite progress in previous research there still 
remains an urgent need for overcoming resistance in pathogens 
using a method which is non-invasive and simple to use in 
antimicrobial formulations.   
Nanocarriers have previously been used to deliver drugs in a way 
which is target specific, increasing the concentration of the drug at 
the desired location.26 This can also reduce the unwanted interaction 
of the drug in healthy tissue, facilitating a general reduced toxic 
effect.27 They can also protect the encapsulated active agent from 
possible degradation or inactivation within a biological system.28 
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Nanocarrier’s must be biocompatible, biodegradable, non-
immunogenic, and not intrinsically toxic.29 Various strategies for 
using nanomaterials as antimicrobials and delivery of antibiotics 
have been recently reviewed.40 Tetracycline itself, being a cationic 
antibiotic has previously been encapsulated into poly(acrylic acid) 
based interpenetrating polymer gels (IPNs),41 however, these are not 
nanocarriers and did not include any bacterial targeting strategy. 
Nanogels are lightly-crosslinked ionisable polymer chains that can 
swell in aqueous solutions when mediated by pH changes. 
Commonly, polymers with carboxyl groups functionality are used to 
swell the nanogel cross-linked scaffold, but other groups such as 
sulphate and hydroxyl can be used.30 Polyacrylic nanogels have 
previously been used to encapsulate and deliver cationic 
antimicrobial molecules such as berberine hydrochloride and 
chlorhexidine di-gluconate.31,32 dual-functionalised shellac 
nanoparticles showed a boost in berberine antimicrobial effect.33  
In the present study, we test a novel method of tetracycline and 
lincomycin delivery, designed to significantly enhance their 
antibiotic action on resistant bacteria. Specifically, these 
cationic antibiotics were encapsulated into the cores of a 
commercially available polyacrylic acid copolymer based 
nanogel, Carbopol Aqua SF1. The surface of the nanogel 
particles was further functionalised with a mid-molecular 
weight (Mw~25,000) biocompatible polyelectrolyte, branched 
polyethylenimine (bPEI; outlined in Figure 1A). We studied the 
antimicrobial efficacy of these antibiotic delivery vehicles 
against validated tetracycline and lincomycin resistant wound 
derived clinical isolates. The cationic antibiotic is encapsulated 
within the interior of the nanogel where it electrostatically 
interacts with partially dissociated COOH groups of the 
polyacrylic acid-based nanogel. Due to the cationic nature of the 
bPEI coating, the modified nanogel particles can adhere 
electrostatically to the negatively charged bacterial cell walls 
which allows the encapsulated antibiotic to be released in a very 
close proximity to the targeted bacteria with the purpose of 
amplifying its antimicrobial effect.  
 Gram-positive bacteria contain an abundance of teichoic acids, 
which are linked to either the peptidoglycan or the cell 
membrane directly. These teichoic acids facilitate a negative 
charge due the presence of phosphate in their molecular 
structure.  Similarly, Gram-negative bacteria contain an outer 
layer of lipopolysaccharides and phospholipids, which confers a 
negative charge to the bacteria.39 This process is illustrated in 
Figure 1C.  This strategy can potentially deliver much higher 
dose of antibiotic directly on the bacteria cell wall that can be 
achieved through oral intake and could temporarily overwhelm 
the bacteria efflux transporters. Additionally, targeted 
nanocarrier-based antibiotic delivery could avoid cytotoxicity by 
reducing the overall concentration of antibiotic required for 
efficacy. Here, for the first time we test this concept on a range 
of resistant and susceptible bacterial species clinically isolated 
from wound samples, in attempt to overcome antibiotic 
resistance without increasing the overall concentration of the 
antibiotic treatment. 
 
Materials and Methods 
Materials 
Carbopol Aqua SF1 nanogel was supplied by Lubrizol, USA, as an 
aqueous suspension (30 wt%).  Polyethylenimine, branched (bPEI) 
was supplied by Sigma-Aldrich (99%), Germany.  Resazurin sodium 
salt (75%, Sigma-Aldrich, UK) was used for cell metabolic activity 
assays and diluted in Dulbecco’s Phosphate Buffered Saline (DPBS) 
(Gibco, Fisher Scientific, UK) at a concentration of 15 mg mL-1.  
CellTiter 96® AQueous One Solution Reagent was purchased from 
Promega, UK and used to measure the metabolic activity of HaCaT 
cells.  Tetracycline hydrochloride and lincomycin hydrochloride were 
supplied by Sigma-Aldrich, UK.  Mueller-Hilton Broth (MHB), Mueller-
Hilton Agar (MHA), tetracycline (30 μg) and lincomycin (15 μg) 
Antimicrobial Susceptibility Disk were supplied by Oxoid, UK. Dey-
Engley neutralising broth was provided by Sigma-Aldrich, UK.  
Dubecco’s Modified Eagle Medium, heated activated Foetal Bovine 
Serum (FBS), and L-Glutamine were delivered by Gibco (Fisher 
Scientific, UK).  Trypsin (10X) was purchased from Sigma-Aldrick, UK) 
and Trypan Blue Solution (0.4% phosphate buffered saline was 
supplied by HyClone™ (GE Healthcare Sciences, UK).  Staphylococcus 
aureus subsp. aureus Rosenbach (ATCC® 29213™) and Pseudomonas 
aeruginosa (Schroeter) Migula (ATCC® 27853™) were purchased from 
ATCC. Wound isolated bacterial species (Table 1) were obtained from 
Hull Royal Infirmary, inoculated on bijoux slopes. Microbank bead 
cryovials (Pro-Lab Diagnostics, Canada) were used to store all species 
long-term at -80 oC according to the manufacturer’s protocol. 
Deionized water purified by reverse osmosis and ion exchange from 
a Milli-Q water system (Millipore, UK or PUR1TE SELECT, UK) was 
used in all our studies.  Consumable plasticware used in the study 
were purchased from Sarstedt (UK), Thermo Scientific (UK), or 
CytoOne (UK) unless otherwise stated.   
Bacterial Culture 
Bacterial stock plates were created by streaking one Microbank bead 
onto an MHA plate and incubating for 24 hours at 37oC to produce 
viable colonies. Overnight (O/N) cultures were prepared by 
incubating a single colony scraped from the MHA stock plates into 10 
mL of MHB for 16 hours at 37oC with 140 rpm shaking (Labnet 211DS 
shaking incubator, Labnet International). For all bacterial assays, O/N 
cultures were adjusted to 0.5 McFarland standard by diluting the O/N 
culture into 0.85 w/v% serial saline until an optical density of 0.08-
0.12 at 625 nm was obtained using a spectrophotometer (Jenway 
7310, Cole-Parmer). These adjusted bacterial saline suspensions 
were then diluted 1:150 into MHB to yield starting concentrations 
between 5 × 105 – 1 × 106 colony forming units per mL (CFU mL-1). 
Table 1.  Clinical isolate bacteria used in this study.   
Genus/Species Origin 
Staphylococcus epidermidis Leg ulcer 
Staphylococcus aureus (methicillin-resistant) Leg ulcer 
Staphylococcus aureus Sebaceous cyst 
Pseudomonas aeruginosa Leg ulcer 
Enterococcus faecalis Ulcer 
Staphylococcus pseudointermedius Burn 
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Figure 2.  The nanogel particle size (A) and zeta potential (B) distribution of 0.02 wt% Carbopol Aqua solution was the diameter measured at pH 5 with a 
Zetasizer. (C) The 0.02 wt% Carbopol Aqua SF1 nanogel mean particle hydrodynamic diameter and (D) mean zeta potential at varying pH. Particle size and zeta 
potential is measured using a DLS. Carbopol Aqua SF-1 was diluted from a 30 wt% stock with two refractive indexes (RI).  pH 4-7 (collapsed nanogel) is measured 
with RI 1.450 and pH 8-12 (swollen nanogel) with RI 1.336 at 25°C.  Each value represents a triple replicate with ± S.D. The lines are guides to the eye. 
Encapsulation of tetracycline and lincomycin into Carbopol Aqua 
SF1 nanogel and its effect on Carbopol stability 
The principle of the encapsulating a cationic antibiotic (as a 
hydrochloride salt) is based on the swelling and deswelling cycle of 
the Carbopol Aqua SF1 at different pH.31 Briefly, a 0.2 wt% aqueous 
dispersion of the nanogel was prepared by adding 6.66 μL of the 30 
wt% stock solution to a beaker and diluting in 10 mL of deionized 
water.  This was then adjusted to pH 8 by adding droplets of 0.25 M 
NaOH whilst been stirred. The dispersion was then warmed to 37 oC.  
An aliquot of 0.2 wt% tetracycline/lincomycin aqueous dispersion 
was prepared by weighing 20 mg of the antibiotic (ABX=tetracycline 
or lincomycin) powder and diluting into 10 mL of deionized water and 
then warming to 37 oC. The 10 mL antibiotic solution was then added 
to the pH 8 nanogel dispersion and shaken for 30 minutes at 37 oC to 
allow the antibiotic to diffuse into and electrostatically bind to the 
swollen Carbopol nanogel. The pH of the ABX-Carbopol solution was 
then reduced to pH 5 using droplets of 0.25 M HCl whilst being stirred 
for another 30 minutes. The ABX-Carbopol solution was then 
centrifuged at 4000 rpm for 15 minutes, the supernatant removed 
and retained for encapsulation efficiency analysis. The pellet was 
washed twice with deionized water and re-dispersed into 10 mL of 
deionized water. The pH was then increased to 8 by gradually adding 
droplets of 0.25 M NaOH and the solution was gently stirred 
overnight. The final ABX-Carbopol solution was reduced to pH 5.5 
using acetate buffer solution. The particle size and zeta potential 
distribution of the ATX-Carbopol dispersion was measured using a 
Malvern Mastersizer as described above.   
Encapsulation efficiency of tetracycline and lincomycin in Carbopol 
Aqua SF1 
The encapsulation efficiency of ABX was measured by analysing the 
supernatant collected from the centrifugation of ABX-Carbopol 
dispersion.  The absorbance of the supernatant was measured at 625 
nm using a spectrophotometer (Jenway 7310, Cole-Parmer).  
Calibration curves of both tetracycline and lincomycin were 
produced by diluting different weights of the antibiotic into 10 mL of 
deionized water to create a range of aqueous solutions of ABX of 
concentration in the range of 0 – 0.2 wt%.  A calibration graph was 
prepared for the absorbance as a function of the ABX concentration. 
A linear regression was used to determine to the unknown 
concentration of the un-encapsulated ABX in the supernatant. The 
encapsulation efficiency of the antibiotic loaded into the Carbopol 
Aqua SF1 was calculated as follows  
𝐸𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
total antibiotic − uncapsulated antibiotic
total antibiotic
100. 
Release kinetics of tetracycline and lincomycin from Carbopol 
Aqua SF1 nanogel formulations 
The release kinetics of the ABX from the Carbopol Aqua SF1 was 
measured by placing the 10 mL 0.2 wt% ABX-Carbopol solution 
into 12-14 kDa dialysis tubing (Serva, Germany) and sealed with 
plastic clips.  The filled dialysis tubing was then placed into 500 
mL of (i) an acetate buffer solution at pH 5.5 or (ii) a phosphate 
buffer at pH 7.5 in order to monitor the amount of released ABX 
at a specific pH over 24 hours at room temperature. 1 mL 
aliquots of the acetate or phosphate buffer solution was 
removed at specific time points and the absorbance measured 
at 625 nm using a spectrophotometer (Jenway 7310, Cole-
Parmer). 1 mL of either acetate of phosphate buffer solution 
was added to the respective solution to retain the volume at 
500 mL. Calibration curves of both tetracycline and lincomycin 
were created by diluting different weights of the ABX into 500 
mL of either acetate or phosphate buffer solutions to create a 
range of buffered solutions of ABX of concentration between 0 
and 0.2 wt%. The amount of ABX released from the Carbopol 
Aqua SF1 nanogel which has transferred into the buffer solution 
through the dialysis membrane pores was determined from the 
calibration curves. The percentage released ABX leaching from 
the nanogel was calculated by the equation: 
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amount of ABX in the buffer solution at a specific time
ABX release (%) = 100.
amount of ABX loaded into the nanogel
  
Functionalisation of ABX-Carbopol Aqua SF1 nanogel with bPEI 
bPEI is a branched cationic polyelectrolyte which was used to reverse 
the surface charge of the ABX-Carbopol Aqua SF1 nanogel particles 
from negative to positive. A 0.005 wt% bPEI aqueous solution was 
produced by weighing a 0.5 mg aliquot of bPEI and placing into a 
beaker and dispersing in a total volume of 10 mL of deionized water 
whilst stirring. 10 mL 0.005 wt% bPEI aliquot was rapidly added to 
the 10 mL 0.2 wt% ABX-0.2 wt% Carbopol dispersion with vigorous 
shaking for 5 minutes.  The resulting mixture was then centrifuged at 
4000 rpm for 15 minutes. The supernatant was discarded, and the 
pellet re-dispersed into 10 mL of deionized water yielding a 0.005 
wt% bPEI-0.2 wt% ABX-0.2 wt% Carbopol Aqua SF1 dispersion which 
was used as a stock for antimicrobial testing against wound 
associated bacterial pathogens.   
Antimicrobial susceptibility testing (AST) Disk Diffusion Test of 
wound species  
A single colony of each species was isolated and placed into 10 mL of 
MHB and grown overnight at 37oC.  The bacteria suspension was then 
diluted to a 0.5 McFarland standard in MHB by measuring the 
turbidity at 625 nm yielding 1-2 × 108 CFU/mL. A cotton swab was 
used to streak a MHA plate lawn.  4  0.5 mm deep MHA plates were 
created by adding 25 mL of molten MHA to a 9 cm round plate and 
left to solidify at room temperature. Tetracycline (30 μg) and 
lincomycin (15 μg) antibiotic disks (both Oxoid, UK) were applied to 
the MHA plates using a disk dispenser (Oxoid, UK), the plates were 
incubated for 18 hours at 35 ±1 oC following EUCAST guidelines. Zone 
of inhibition diameters were illuminated using a lightbox and the 
images measured in mm using a ruler, the diameter was measured 
across 3 lines and the mean determined to be the zone of inhibition.   
Cell viability of HaCaT cells treated with free ABX and Carbopol 
nanogel-formulated ABX.   
HaCaT cells (an immortalised human keratinocyte cell line, sourced 
from AddexBio, San Diego) were cultured in DMEM supplemented 
with 10% FBS and 1% L-Glutamine in humidified conditions at 37 oC, 
5% CO2 in T75 flasks until a confluency of 80% was achieved, 
determined by visualisation with a light microscope. Passaging was 
done at 80% confluency to ensure the cells remained in the 
exponential phase for experimentation. Passaging was performed by 
removing spent media and washing in DPBS and incubating with 1x 
Trypsin at 37 oC 5% CO2 for 5 min until the cells were detached and 
in suspension. The trypsin was then neutralised with using 1:1 
volumetric ratio of fresh DMEM and gently centrifuged at 1000 rpm 
for 5 min, the supernatant was aspirated, and the pellet resuspended 
in DMEM (supplemented as above) at a 1:6 ratio and transferred into 
a fresh T75 flask. Surplus cells were diluted and 1 × 104 HaCaT cells 
were seeded in 50 mL of DMEM (ABX free) supplemented with 2 wt% 
FBS (foetal bovine calf serum) into a 96-well plate and incubated for 
24 hours at 37 oC 5% CO2. The medium was then removed and 
replaced with treatment infused media (free ABX or the formulated 
nanogel-encapsulated ABX) and incubated for 24 hours after which 
it was replaced with fresh DMEM and 20 μL of CellTiter 96® Aqueous 
One Solution Reagent (Promega, UK) where it was incubated for 3 
hours at the same conditions. The absorbance was then read at 492 
nm. These data were calculated into cell count data using the Beer-
Lambert extinction coefficient law using absorbance values from a 
fixed number of cells in media. The HaCaT cell viability assay was 
repeated in three independent experiments. 
Minimum Inhibitory Concentration (MIC) 
The bacteriostatic properties of the bPEI-coated ABX-loaded 
Carbopol nanogel particles and its spectrum of activity were 
measured in comparison to equivalent concentrations of free 
tetracycline or lincomycin. The antimicrobial activity was tested 
against each of the strains described in Table 1.   Briefly, O/N cultures 
of each strain were prepared as described in above.  100 μL of each 
strain suspension was added to the wells of a 96-well microtiter plate 
yielding 5 × 104 - 1 × 105 cell per well.  An aliquot of bPEI-coated-0.2 
wt% ABX-0.2 wt% Carbopol suspension was created.  This was 
centrifuged at 4000 rpm for 5 minutes and re-suspended into 10 mL 
of MHB.  2-fold dilutions of this suspension were created in separate 
aliquots and 50 μL added to descending rows of bacteria on the 
microtiter plate.  Equivalent 2-fold dilutions of the free ABX were 
added to separate columns to for comparison (50 μL per well).  The 
plates were incubated for 20 hours at 37 oC.  20 μL of resazurin 
sodium salt (0.15 mg/mL in DPBS) was added to each well and 
incubated at 35 oC for 2 hours.  The absorbance was recorded using 
a spectrophotometer (Jenway 7310, Cole-Parmer). The resazurin in 
the presence of viable cells is reduced to resorufin by the bacterial 
co-enzyme NAHD, indicating the cells remain metabolically active 
and viable (see Figure S1, ESI). The MIC was determined to be the 
lowest concentration of active antimicrobial agent which inhibited 
the growth of each strain. The MIC assay was repeated in three 
independent experiments. 
Time-kill assays 
Killing curves were performed against each representative strain to 
determine the time taken for the active agent in influence total 
bacterial cell populations.  O/N cultures were prepared yielding a 10 
mL MHB aliquots with 5 × 105 – 1 × 106 cells per mL.  10 mL of 0.005 
wt% bPEI-coated-0.2 wt% ABX-0.2 wt% Carbopol nanogel was added 
to each tube and incubated for 24 hours at 37 oC with 140 rpm 
shaking.  At time points 0, 1, 2, 3, 4, 6, and 24 hours a 100 μL sample 
was removed from each treatment tube and added to 900 μL of Dey-
Engley Neutralising broth. 100 mL aliquots from each serial dilution 
tube were plated onto MHA plates and incubated for 24 hours at 37 
oC and enumerated. The time-kill assay was repeated in three 
independent experiments. 
Statistical analysis  
Data were expressed as average values ± standard deviations of the 
mean. P-values of less than 0.05 were considered significant. All One-
Way ANOVAs and Tukey’s post-test statistical analysis were 









Figure 3.  (A) The mean particle diameter and (B) zeta potential of 0.1, 0.15, and 0.2 wt% Carbopol Aqua SF1 nanogel after encapsulation of tetracycline at 
various concentrations and (C) The particle diameter and (D) zeta potential of 0.1, 0.15, and 0.2 wt% Carbopol Aqua SF1 nanogel after encapsulation of 
lincomycin at various concentrations at pH 6.  0.1, 0.15, and 0.2 wt% Carbopol Aqua SF1 nanogel suspensions were created and mixed with 
tetracycline/lincomycin hydrochloride at varying concentrations.  Each value represents a triple replicate with ± S.D. The lines are guides to the eye. The legend 
is representative of all Figures 3A, 3B, 3C, and 3D. 
 
 
SEM imaging of the treated cells 
Cells were removed from their media by centrifugation at 2000 rpm 
for 5 min and washed and resuspended in PBS buffer. The washing 
process was done three times to remove access media peptone. The 
cells were then fixed in a 1 wt% glutaraldehyde PBS buffer solution 
for 1 hour at room temperature, the cells were then centrifuged 
at 2000 rpm and the pellet washed with deionized water three 
times to remove excess glutaraldehyde, the cell samples were 
then re-suspended in and dehydrated 50%/75%/90% and 
absolute ethanol solutions for 30 minutes per each ethanol 
concentration. Cells were then swabbed onto a glass slide and 
submerged into absolute ethanol and dried using liquid CO2 at 
its critical point using an E3000 Critical Point Dryer (Quorum 
Technologies, UK) and then coated in 10 nm Carbon. The 
samples were imaged using an Ultra-High-Resolution Scanning 
Electron Microscope using cold field emission (Hitachi SU8230, 
Japan).   
Results and discussion 
Encapsulation of tetracycline and lincomycin into Carbopol Aqua 
SF1 nanogel 
The particle size and zeta potential of Carbopol SF-1 were 
measured using a Malvern Zetasizer Nano ZS at 25oC using a 
refractive index of 1.450.  A 30 wt% stock solution was diluted 
to 0.02 wt% in deionized water. The Carbopol nanogel 
suspension has an average particle diameter of 100 nm and a 
zeta potential of -30 ± 1.82 mV (see Figures 2A and 2B, 
respectively).  Figure 2C shows the useful swelling effect of the 
Carbopol Aqua SF1 nanogel and how pH changes in the solution 
can be used to mediate this. There is a change in the nanogel 
particle diameter from approximately 100 nm to 300 nm when 
adjusting the pH from 6 to 8, which is due to the COOH groups 
of the Carbopol undergoing de-protonation to COO- in a basic 
solution. The electrostatic repulsion of these negatively charged 
-COO- groups causes the particle swelling effect and facilitates 
the subsequent electrostatic binding of cationic compounds. 
The negative zeta potential of the swollen nanogel, which 
remains between -25 mV and -29 mV at a pH range of 4 to 12 
(Figure 2D), shows the anionic nature of the Carbopol SF1 
nanogel.  This was exploited to bind the cationic antibiotics 
(ABX), tetracycline hydrochloride, and lincomycin hydrochloride 
to the cores of the nanogel. The particle size of the de-swelled 
nanogel with encapsulated ABX is dependent on the ABX 
concentration with which the nanogel has been incubated. 
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Figure 4.  The zeta potential of bPEI coated antibiotic-Carbopol particles at pH 
5.5 measured at time intervals after preparation.  A Malvern Zetasizer was 
used to measure the particle diameter and zeta potentials at a refractive 
index of either 1.450 (below pH 7) or 1.336 (above pH 7).  Each value 
represents average triplicate measurements with error bars representing the 
± S.D.  The lines are guides to the eye. 
 
Figures 3A and 3C shows the relationship between the ABX 
concentration and the nanogel colloid stability which has to be 
maintained. This requires the ABX concentration to be 
proportional to the nanogel concentration within certain range.  
For both the tetracycline and the lincomycin solutions loaded in 
the 0.2 wt% Carbopol-0.2 wt% ABX allows a nanogel particle 
shrink to approximately 110 ± 2 nm. However, for increased ABX 
concentrations and lower concentrations of the nanogel, the 
particle may undergo aggregation and the formation of less 
stable nanogel, approximately 160 ± 5 nm and 220 ± 5.12 nm 
for tetracycline and lincomycin, respectively. 
The optimal combination of 0.2 wt% ABX-0.2 wt% Carbopol 
Aqua SF1 nanogel formulation was chosen as this allowed the 
highest encapsulation efficiency of ABX without compromising 
the nanocarrier colloidal stability. The zeta potential of the 
collapsed ABX-loaded nanogel was unaffected by the 
concentration of the encapsulated ABX. Figure 3B and 3D 
(tetracycline and lincomycin respectively) show the zeta 
potential of 0.2 wt% Carbopol remains stable at approximately 
-39 ± 1mV whether loaded with lower or higher concentrations 
of ABX, indicating that the ABX concentration does not impact 
on the overall surface charge of the collapsed nanogel particles. 
The purpose of encapsulating the antibiotic was to provide a 
targeted delivery system which would release it in close 
proximity to the microbial cell wall. To achieve this the 0.2wt%-
0.2 wt% ABX formations were mixed with very low 
concentrations (0.005 wt%) of the cationic polyelectrolyte bPEI 
(branched polyethyleneimine) to reverse the surface charge of 
the collapsed nanogel particles and induce electrostatic 
attraction to the negative bacterial cell wall.  0.005 wt% bPEI 
was chosen as it was the optimal concentration that can reverse 
the surface charge of the nanogel particles and maintain 
optimal colloidal stability of the nanocarrier.  
 
Figure 5.  (A) Tetracycline and (B) lincomycin release kinetics in different pH solutions.  
10 mL of 0.2 wt% ABX -0.2 wt% Carbopol suspension was placed in a 10-12 kD MWKO 
dialysis bag. The dialysis bag was submerged into either 250 mL of phosphate or acetate 
buffer (pH 7.5 and 5.5, respectively) whilst stirred.  1 mL aliquots were taken at specific 
time points on the absorbance of the aliquot equated into the concentration of ABX in 
the buffer using a standard calibration curve. Absorption was measured at 625 nm. 
 
Figure S3 (ESI) shows increased concentrations of bPEI-induced 
aggregation of the nanogel particles with no detectable further 
increase in their zeta potential. Figure 4 shows the zeta 
potential of the ABX-loaded nanogel particles was reversed 
from approximately -39 mV to +(25-28) mV for both tetracycline 
and lincomycin loaded in Carbopol Aqua SF1 after coating with 
bPEI. Our measurements showed that the zeta potential of the 
bPEI-coated nanogel particles remained very stable and positive 
for more than 24 hours indicating the bPEI has coated the 
particle surface, conferring a long-lasting positive surface 
charge. 
Encapsulation efficiency and release kinetics of tetracycline and 
lincomycin in Carbopol Aqua SF1 
The supernatant of the ABX-nanogel formation was retained after 
centrifuging to determine how much ABX the nanogel has been 
encapsulated in the swelling and de-swelling process.  Figure S2A and 
S2B (ESI) show the absorbance of the tetracycline and lincomycin in 
deionized water reduced to pH 5 using 0.25 M HCl.  
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Figure 6. Zeta potential of bacterial wound species. A colony of each species was 
inoculated into 10 ml of MHB and grown overnight at 37 oC with constant shaking.  The 
bacterial suspension was the centrifuged for 10 min at 5000 rpm.  The supernatant was 
discarded, and the pellet washed twice with deionized water. The pellet was 
resuspended in 45 ml of deionized water. 1 mL of this suspension was placed in a quartz 
cuvette and zeta potential was measured using the Dipstick probe and Malvern Zetasizer 
nano ZS. The refractive index was 1.384 and the absorption 1.000. N=3 with ± S.D.   
 
This calibration curve was used to compare the absorbance readings 
obtained from the supernatant created during the centrifugal 
process used in forming the ABX-loaded nanogel particles. A linear 
regression equation was used to determine the ABX concentration in 
the supernatant and from this the ABX concentration retained within 
the nanogel. Tables S1 and S2 (ESI) show that increasing the 
temperature to 37 oC while incubating the Carbopol nanogel and the 
ABX solutions prior to mixing, and the duration of the mixing both 
affect the ABX amount successfully encapsulated. In both the 
tetracycline and lincomycin formulations, the 30 min/37 oC mixing 
conditions yielded the highest encapsulation efficiency, with 89.9% 
for tetracycline and 79.5% for lincomycin, respectively.  The release 
kinetics of ABX from the ABX-loaded nanogel formations was tested 
to examine how the ABX release is affected by the pH of the solution. 
Figures 5A and 5B show that tetracycline and lincomycin are slowly 
released from the interior of the nanoparticles over a period of 24 
hours. In both the tetracycline and lincomycin loaded nanogel-
formulations, their release from the nanogel is higher in the PBS (pH 
7.5) compared to the acetate buffer (pH 5.5).  In both the acetate and 
phosphate saline buffers, there is a large release of both tetracycline 
and lincomycin within the first 5 hours between 30% to 70% for the 
acetate buffer and PBS, respectively. Further release of the antibiotic 
is much slower and gradual for the remaining time. The increased 
ABX release rates in the phosphate buffer solutions can be explained 
by the partial swelling of the nanogel at the higher pH, which will 
allow ABX to diffuse faster from its interior. 
 
 
Figure 7.  Zones of inhibition (AST disk diffusion test) for wound isolates and 
reference strains. 15 μg lincomycin disks (left) and 30 μg tetracycline disks 
(right). 
 
The continued release of ABX from the nanogel particles over a long 
period of time could also potentially be highly beneficial in an 
antimicrobial context, as the ABX will be delivered locally on the 
surface of the bacterial cell continuously for a long period of time. 
We are not aware of previous studies in which these antibiotics were 
encapsulated into nanogel particles of the same nanocarrier 
chemistry. These results allow comparison with typical encapsulation 
efficiencies with other cationic antimicrobial molecules such as 
berberine hydrochloride31 and chlorhexidine digluconate.32,23 Our 
studies show that encapsulation of these cationic antimicrobials has 
proven successful within anionic microgels and dual functionalised 
shellac nanocarriers with comparable encapsulation efficiency. 
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Figure 8.  HaCaT viability after treatment with tetracycline concentrations and Carbopol formulated tetracycline/lincomycin and individual formulation 
constituents.  1 × 104 HaCat cells were seeded in 50 ml of DMEM (antibiotic free) supplemented with 2 wt% FBS (foetal bovine calf serum) into a 96-well plate 
and incubated for 24 hours at 37 oC in 5% CO2 atmosphere. The medium was then removed and replaced with treatment infused media. 
 
Figure S4 (ESI) shows SEM images acquired of (A) a sample of 
0.2 wt% Carbopol loaded with 0.2 wt% lincomycin, (B) 0.005 
wt% bPEI-0.2 wt% lincomycin-0.2 wt% Carbopol, and (C) 0.2 
wt% Carbopol nanogel (empty nanocarrier). Lincomycin was 
chosen for the characterisation due to the presence of a sulphur 
in the molecular structure. One can see from the EDX spectra 
the presence of sulphur in the lincomycin-loaded Carbopol 
nanogel particles after the particles have been washed from the 
excess of lincomycin.  This spectra peak is not present in the 
unloaded nanocarrier (Figure S4C). We conclude from this result 
that lincomycin has been successfully loaded into the nanogel 
particles, also in agreement with the dynamic light scattering 
results presented in Figure 5. 
Zeta potential of wound-relevant bacterial species  
The action of the Carbopol encapsulated ABX, functionalised with 
bPEI to yield a positive surface charge is to facilitate a sustained and 
targeted ABX delivery platform, which is based on the electrostatic 
adhesion between the nanogel particles and the bacterial cell wall. 
Seven wound-associated bacterial pathogens, along with a S. aureus 
reference strain (ATCC - 21213) and P. aeruginosa reference strain 
(ATCC - 27853) were cultured overnight and centrifuged for 10 
minutes at 5000 rpm.  The pellet was re-dispersed into deionized 
water for zeta potential measurement. The zeta potential for Gram-
negative species was between -30 mV and -37 mV, while the six 
Gram-positive species had a very similar zeta potential of -20 ± 2 mV 
(Figure 6). As expected, the additional negatively charged 
lipopolysaccharide (LPS) confers higher negative surface charge for 
the Gram-negative species. Crucially, all bacteria tested displayed a 
negative charge which should allow electrostatic adhesion between 
the bacterial cell wall and the cationic nanogel formulations. 
Antimicrobial susceptibility testing (AST) Disk Diffusion Test of 
wound species 
Tetracycline and lincomycin disks were placed on bacterial lawns of 
the nine selected bacterial species to confirm antibiotic resistance 
(Figure 7). The zone of inhibition surrounding the disk was measured 
in mm using a ruler and compared to reference values from the 
European committee of antimicrobial susceptibility testing 
(EUCAST).34 Table S3 (ESI) shows the results from the antimicrobial 
susceptibility disk diffusion testing. S. aureus (both strains), S. 
epidermidis, MRSA, and S. pseudointermedius were susceptible to 
both tetracycline and lincomycin. P. aeruginosa (both strains) and E. 
faecalis were resistant to both tetracycline and lincomycin.  Figure 7 
shows the clear zones of inhibition which surround the species which 
confer resistance to either antibiotic. 
Viability of HaCaT cells treated with tetracycline/lincomycin and 
Carbopol encapsulated tetracycline/lincomycin and its individual 
constituents   
A preliminary human cell cytotoxicity experiment was performed on 
HaCaT cells to assess if the Carbopol Aqua SF1 nanogel formulations 
(and individual constituents) were toxic to human cells compared to 
the free antibiotics. Interestingly, Figure 8 shows that after 24 
hours of incubation 0.2 wt%, 0.005 wt% bPEI, and 0.2 wt% bPEI-
0.2 wt% Carbopol (empty carrier) showed no toxic effect 
compared to the untreated cell controls. This indicates the 
individual components of the nanogel formulation did not lead 
to a reduction in viable cell number after 24 hours. Treatments 
with free tetracycline and lincomycin were used at 
concentrations 0.2, 0.3, and 0.4 wt% and showed a slight 
reduction in total cell counts when compared to the control, 
approximately 20% to 25% for lincomycin and tetracycline at 0.4 
wt% respectively. The 0.2 wt% Carbopol-0.2 wt% ABX-0.005 
wt% bPEI formulation showed toxicity in line with 0.2% free 
antibiotic. This indicates that the nanogel-loaded antibiotics 
confer no increased toxicity to HaCaT cells, both when 
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encapsulating an antibiotic and as an empty nanocarrier.  This 
formulation could have a potential topical application to treat 
infected wounds. HaCaT cells represent a good proxy for a typical 
skin keratinocyte which would be exposed to the ABX-loaded 
nanocarrier formulation during the wound treatment. 
   
 
Figure 9. Time kill assays against clinical wound isolates and selected reference species.  Tetracycline and 0.005 wt% bPEI-coated 0.2 wt% tetracycline loaded in 0.2 wt% Carbopol 
(CLC), 0.005 wt% free bPEI and 0.005 wt% bPEI-coated 0.2% Carbopol (empty nanocarrier) tested against several clinical isolate wound bacteria. The results are presented as means 
(n = 3).  The lines are guides to the eye. < 0.05 is considered significant. *P <0.05, **P <0.01, ***P <0.001 compared to the free tetracycline. 
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Figure 10. Time kill assays against clinical wound isolates and selected reference species.  Lincomycin and 0.005 wt% bPEI-coated 0.2 wt% lincomycin loaded 
in 0.2 wt% Carbopol (CLC), 0.005 wt% free bPEI and 0.005 wt% bPEI-coated 0.2% Carbopol (empty nanocarrier) tested against several clinical isolate wound 
bacteria. The results are presented as means (n = 3).  The lines are guides to the eye. < 0.05 is considered significant.   *P <0.05, **P <0.01, ***P <0.001 
compared to free lincomycin. 
 
Antibacterial activity of bPEI-coated tetracycline/lincomycin 
loaded Carbopol Aqua SF1 on clinical wound isolates 
Figures 9 and 10 shows time kill evaluation of 0.005 wt% bPEI-
0.2 wt% Carbopol-0.2 wt% ABX (tetracycline and lincomycin 
respectively).  The uncoated Carbopol nanogel and bPEI coated 
nanogel were included as unloaded controls. Exponential 
growth was observed over 24 hours for the nine wound-
relevant bacteria under no treatment conditions and in the 
presence of each control component (0.2 wt% nanogel, 0.005 
wt% bPEI, and the 0.005 wt% coated 0.2 wt% nanogel). S. 
aureus (clinical isolate and reference strain), S. epidermidis, 
MRSA, and S. psuedointermeduis showed after 24 hours that 
both tetracycline and lincomycin had a bacteristatic effect on 
growth, with a small reduction in bacteria number over the 24 
hours. By contrast, P. aeruginosa  (clinical isolate and reference 
strain) and  E. faecalis showed no reduction in cell population 
when treated with 0.2 wt% free tetracycline and lincomycin 
compared to the untreated growth control. These results are in 
agreement with the AST disk diffusion results shown in Figure 7. 
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Figure 11. (A) MIC of tetracycline and nanogel-encapsulated tetracycline, (B) MIC of lincomycin and nanogel-encapsulated lincomycin.  All nanogel particles 
were coated with bPEI.  “>” indicates that a concentration greater than 0.2 wt% is needed to inhibit bacterial growth. 
 
The bPEI-coated nanogel encapsulated tetracycline and lincomycin 
were highly effective against S. aureus (reference strain) and S. 
epidermidis causing a >5 log reduction in cell population after 
approximately 3 hours.  A similar result is observed in MRSA, S. 
psuedointermedius and E. faecalis with a >5 log reduction observed 
with the nanogel-encapsulated tetracycline at 3 hours, and after 24 
hours with lincomycin.  After 24 hours the wound isolated S. aureus 
has shown a >5 log reduction with encapsulated tetracycline and a 
>1 log reduction with encapsulated lincomycin. P. aeruginosa (ATCC 
and clinical isolate) showed an appromimate >4 log reduction with 
the nanogel-encapsulated tetracycline and lincomycin compared to 
equivalent concentrations of the free antibiotic.  Collectively, these 
data show that the cationic antibiotic delivery system enhances 
antimicrobial action of tetracycline and lincomycin, across all nine 
bacteria evaluated in this study. Crucially,  cationic nanocarrier-
based antibiotic delivery was able to overcome antimicrobial 
resistance across several isolates, conferring > 5 log reduction within 
24 hours (Table S6, ESI).  
The minimum inhibitory concentrations (MIC) for tetracycline and 
lincomycin are shown in Figure 11, the data is also shown in Tables 
S4 and S5 (ESI). The ability of the nanogel-encapsulated tetracycline 
to inhibit growth was demonstrated through all nine species with up 
to 8 × MIC reductions shown. The P. aeruginosa strains also showed 
much reduced MIC concentrations when compared to free 
tetracycline, both 8 × MIC. This effect was also mirrored with the 
nanogel-encapsulated lincomycin when compared to free 
lincomycin. Similar to nanogel-encapsulated tetracycline, there 
were reductions in the MIC of nanogel-encapsulated lincomycin 
compared to free lincomycin in solution.  This was seen across 
all eight species, ranging from 8 × MIC to 2 × MIC. Interestingly, 
in the P. aeruginosa (ATCC strain and clinical isolate) and E. 
faecalis there was 8 × MIC compared to free lincomycin, 
providing evidence the nanogel-encapsulated lincomycin also 
facilitates an improved inhibitory effect. The increased 
antimicrobial efficiency of the nanogel-encapsulated antibiotics 
would also be advantageous in case of susceptible bacteria as a 
reduced concentration of antibiotic is required to achieve a 
comparable result to that of the free antibiotic. This has potential 
benefits in reducing possible toxicities associated with antibiotic use, 
and a potential reduction in cost, as the antibiotic is considerably 
more expensive than the Carbopol nanogel Aqua SF1 and bPEI. 
The most important benefit of the nanogel-encapsulated 
tetracycline and lincomycin formulations is their ability to be 
effective against species which have demonstrated resistance to 
these antibiotics. We envisage that this could be due to the sustained 
high concentration of the antibiotic localised to the cell wall of the 
bacteria being able to overwhelm efflux pumps, which are able to 
actively remove free antibiotic. Figure 12 shows SEM images of 
P.aeroginosa after treatment with bPEI-coated tetracycline loaded 
Caropol nanogel which demonstrates the accumulation of the 
surface functionalised nanogel particles on the surface of the anionic 
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Figure 12.  SEM images of P. aeruginosa before and after treatment.  (A) shows the control sample of non-treated  P. aeruginosa after 24 hours of growth.  (B-
D) shows P. aeruginosa after 24 hours treatment with 0.005 wt% bPEI-0.2 wt% tetracycline-0.2 wt% Carbopol. 
Conclusions 
We have developed a novel surface functionalised nanocarrier for 
tetracycline and lincomycin by using lightly cross-linked polyacrylic 
acid-based nanogels (Carbopol Aqua SF1) coated with a 
biocompatible cationic polyelectrolyte (bPEI). We show that this 
approach significantly enhanced the antimicrobial action against a 
range of wound isolated pathogens. Crucially, the bPEI surface 
coated nanogel with encapsulated antibiotics had an enhanced 
effect on several bacterial species which were validated to be 
resistant to either tetracycline or lincomycin. This enhanced 
antibiotic efficacy is likely due to favourable electrostatic attraction 
between the positively charged bPEI-coated antibiotic-loaded 
nanogel particles and the negatively charged bacterial cell wall. This 
is mediated by the attachment of the nanocarrier particles which 
then locally release the encapsulated antibiotic in much higher local 
concentrations than the free antibiotic at the same overall 
concentration. We also showed that the cytotoxicity of the 
antibiotics loaded in these nanocarriers on human keratinocyte cell 
is practically negligible at the range of concentrations which kill both 
resistant and susceptible bacteria. Antimicrobial resistance is a 
growing clinical epidemic. This novel method for bacteria-targeted 
topical antibiotic application offers an important new opportunity to 
extend the clinically useful life-span of existing antibiotics, using 
inexpensive materials, while reducing future bacterial antibiotic 
resistance. 
Supplementary Information 
The enclosed Electronic supplementary information file (ESI) 
contains tabulated data for the minimal inhibitory concentration for 
the free and nanocarrier-loaded se antibiotics on planktonic bacteria. 
We also enclose EDX and DLS data on the nanocarrier loaded with 
ABX in comparison with the empty nanocarrier. 
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